281 related articles for article (PubMed ID: 32986290)
1. Experimental Evolution of Antifungal Resistance in Cryptococcus neoformans.
Bermas A; Geddes-McAlister J
Curr Protoc Microbiol; 2020 Dec; 59(1):e116. PubMed ID: 32986290
[TBL] [Abstract][Full Text] [Related]
2. Combatting the evolution of antifungal resistance in Cryptococcus neoformans.
Bermas A; Geddes-McAlister J
Mol Microbiol; 2020 Nov; 114(5):721-734. PubMed ID: 32697029
[TBL] [Abstract][Full Text] [Related]
3. Activity of VT-1129 against Cryptococcus neoformans clinical isolates with high fluconazole MICs.
Nielsen K; Vedula P; Smith KD; Meya DB; Garvey EP; Hoekstra WJ; Schotzinger RJ; Boulware DR
Med Mycol; 2017 Jun; 55(4):453-456. PubMed ID: 27664991
[TBL] [Abstract][Full Text] [Related]
4. Molecular typing, in vitro susceptibility and virulence of Cryptococcus neoformans/Cryptococcus gattii species complex clinical isolates from south-eastern Brazil.
Grizante Barião PH; Tonani L; Cocio TA; Martinez R; Nascimento É; von Zeska Kress MR
Mycoses; 2020 Dec; 63(12):1341-1351. PubMed ID: 32869413
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of antifungal activity of cinnamaldehyde against Cryptococcus neoformans var. grubii.
Neelabh ; Singh K
Folia Microbiol (Praha); 2020 Dec; 65(6):973-987. PubMed ID: 32617865
[TBL] [Abstract][Full Text] [Related]
6. Antifungal susceptibility of Cryptococcus neoformans to amphotericin B and fluconazole.
Khyriem AB; Sujatha S; Parija SC
Indian J Pathol Microbiol; 2006 Apr; 49(2):307-8. PubMed ID: 16933750
[TBL] [Abstract][Full Text] [Related]
7. Molecular typing and in vitro resistance of Cryptococcus neoformans clinical isolates obtained in Germany between 2011 and 2017.
Selb R; Fuchs V; Graf B; Hamprecht A; Hogardt M; Sedlacek L; Schwarz R; Idelevich EA; Becker SL; Held J; Küpper-Tetzel CP; McCormick-Smith I; Heckmann D; Gerkrath J; Han CO; Wilmes D; Rickerts V
Int J Med Microbiol; 2019 Sep; 309(6):151336. PubMed ID: 31444102
[TBL] [Abstract][Full Text] [Related]
8. Molecular identification, antifungal resistance and virulence of Cryptococcus neoformans and Cryptococcus deneoformans isolated in Seville, Spain.
Gago S; Serrano C; Alastruey-Izquierdo A; Cuesta I; Martín-Mazuelos E; Aller AI; Gómez-López A; Mellado E
Mycoses; 2017 Jan; 60(1):40-50. PubMed ID: 27633849
[TBL] [Abstract][Full Text] [Related]
9. A systematic review of fluconazole resistance in clinical isolates of Cryptococcus species.
Bongomin F; Oladele RO; Gago S; Moore CB; Richardson MD
Mycoses; 2018 May; 61(5):290-297. PubMed ID: 29377368
[TBL] [Abstract][Full Text] [Related]
10. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
11. A titanic drug resistance threat in Cryptococcus neoformans.
Zafar H; Altamirano S; Ballou ER; Nielsen K
Curr Opin Microbiol; 2019 Dec; 52():158-164. PubMed ID: 31765991
[TBL] [Abstract][Full Text] [Related]
12. Susceptibility profile and epidemiological cut-off values of Cryptococcus neoformans species complex from Argentina.
Córdoba S; Isla MG; Szusz W; Vivot W; Altamirano R; Davel G
Mycoses; 2016 Jun; 59(6):351-6. PubMed ID: 26865081
[TBL] [Abstract][Full Text] [Related]
13. A Mechanosensitive Channel Governs Lipid Flippase-Mediated Echinocandin Resistance in Cryptococcus neoformans.
Cao C; Wang Y; Husain S; Soteropoulos P; Xue C
mBio; 2019 Dec; 10(6):. PubMed ID: 31822582
[TBL] [Abstract][Full Text] [Related]
14. Antifungal susceptibility of clinical and environmental Cryptococcus neoformans and Cryptococcus gattii isolates in Jabalpur, a city of Madhya Pradesh in Central India.
Gutch RS; Nawange SR; Singh SM; Yadu R; Tiwari A; Gumasta R; Kavishwar A
Braz J Microbiol; 2015; 46(4):1125-33. PubMed ID: 26691471
[TBL] [Abstract][Full Text] [Related]
15. Amino acid substitution in Cryptococcus neoformans lanosterol 14-α-demethylase involved in fluconazole resistance in clinical isolates.
Bosco-Borgeat ME; Mazza M; Taverna CG; Córdoba S; Murisengo OA; Vivot W; Davel G
Rev Argent Microbiol; 2016; 48(2):137-42. PubMed ID: 27311753
[TBL] [Abstract][Full Text] [Related]
16. Molecular epidemiology and antifungal susceptibility of Cryptococcus neoformans isolates from Ugandan AIDS patients.
Pfaller M; Zhang J; Messer S; Tumberland M; Mbidde E; Jessup C; Ghannoum M
Diagn Microbiol Infect Dis; 1998 Nov; 32(3):191-9. PubMed ID: 9884835
[TBL] [Abstract][Full Text] [Related]
17. Response to therapy in patients with cryptococcosis and AIDS: Association with in vitro susceptibility to fluconazole.
Agudelo CA; Muñoz C; Ramírez A; Tobón AM; de Bedout Bact C; Cano LE; Restrepo A
Rev Iberoam Micol; 2015; 32(4):214-20. PubMed ID: 25637338
[TBL] [Abstract][Full Text] [Related]
18. Cryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistance.
Paul S; Doering TL; Moye-Rowley WS
Fungal Genet Biol; 2015 Jan; 74():1-9. PubMed ID: 25445311
[TBL] [Abstract][Full Text] [Related]
19. Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.
Hope W; Stone NRH; Johnson A; McEntee L; Farrington N; Santoro-Castelazo A; Liu X; Lucaci A; Hughes M; Oliver JD; Giamberardino C; Mfinanga S; Harrison TS; Perfect JR; Bicanic T
mBio; 2019 Dec; 10(6):. PubMed ID: 31796539
[TBL] [Abstract][Full Text] [Related]
20. Molecular epidemiology and in vitro antifungal susceptibility testing of 108 clinical Cryptococcus neoformans sensu lato and Cryptococcus gattii sensu lato isolates from Denmark.
Hagen F; Hare Jensen R; Meis JF; Arendrup MC
Mycoses; 2016 Sep; 59(9):576-84. PubMed ID: 27061834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
